

LIST OF FIGURES:

FIGURE TITLE	PAGE NO.
Fig 1.1: Platelet formation release in the blood	2
Fig 1.2: Overview of megakaryocyte production of platelets	3
Fig 1.3: Size Comparison of Blood Corpuscles	4
Fig 1.4 : Diagram representing structure of Platelets	5
Fig 2a.1: Effect of CPLE on Blood platelet counts of animals in dose dependent and time dependent manner.	37
Fig 2a.2: Effect of Aqueous extract of <i>Carica papaya</i> leaves extract Serum Creatinine levels in rats	38
Fig 2a.3: Effect of Aqueous extract of <i>Carica papaya</i> leaves extract Serum Urea levels in rats	39
Fig 2a.4: Effect of Aqueous extract of <i>Carica papaya</i> leaves extract Serum Acid Phosphatase levels in rats	40
Fig 2a.5: Effect of Aqueous extract of <i>Carica papaya</i> leaves extract Serum Alkaline Phosphatase levels in rats	41
Fig 2a.6: Effect of Aqueous extract of <i>Carica papaya</i> leaves extract SGPT levels in rats	42
Fig 2a.7: Effect of Aqueous extract of <i>Carica papaya</i> leaves extract SGOT levels in rats	43
Fig 2a.8: Histopathological studies of Acute Toxicity	44
Fig 2a.9: Histopathological studies in Sub Chronic toxicity	45
Fig 2b.1: Graph representing assessment of cytotoxicity of CPLE using MTT assay	66
Fig 2b.2: Graph representing assessment of cytotoxicity of Caripill using MTT assay	66
Fig 2b.3: Graph representing quantification of Intracellular levels of ROS.	68
Fig. 2b.4: Graph representing IL-6 levels in HEPG2 cells supernatant	69

FIGURE TITLE	PAGE NO.
Fig. 3.1: Effect of different drugs on Platelet count in model making of Experimental Thrombocytopenia	83
Fig. 3.2 <i>In vivo</i> Biotinylation of Platelets for immune thrombocytopenia model	84
Fig.3.3 <i>In vivo</i> Biotinylation of Platelets for immune Thrombocytopenia model 6h antibody post induction	85
Fig 3.4: <i>In vivo</i> Biotinylation of Platelets for immune Thrombocytopenia model 12 Hrs antibody post induction	86
Fig 4.1: Role of Thrombopoetin in Megakaryopsis	94
Fig 4.2: Effect of various concentration of CPLE on platelet count in <i>Rattus rattus norvegicus</i>	106
Fig 4.3 Flowcytometric representation of Platelet population in Control group.	107
Fig. 4.4: Flowcytometric representation of Platelet population in Antibody (alone) group.	108
Fig. 4.5: Flowcytometric representation of Platelet population in Group treated with CPLE.	109
Fig. 4.6 : Flowcytometric representation of Platelet population in Antibody + CPLE group.	110
Fig 4.7: Flow cytometric representation of Thiazole Orange (TO) treated platelet, to assess the Reticulocyte count	111
Fig 5.1: Representative PCR-RFLP gel image of IL-4-590 polymorphism	130
Fig 5.2: Representative PCR-RFLP gel image of IL-4-Intron 3 VNTR polymorphism	131
Fig 5.3: Representative PCR-RFLP gel image of IL-10-592 polymorphism	132
Fig 5.4: Representative PCR-RFLP gel image of IL-10-1082 polymorphism	133
Fig 5.5: Representative PCR-RFLP gel image of TNF- α -308 G/A polymorphism	134
Fig 5.6: Representative PCR-RFLP gel image of TNF-B +252 A/G polymorphism	135

LIST OF TABLES:

TABLE TITLE	PAGE NO.
Table 1.1: List of Drugs/ Chemicals with their action/clinical use and plant source	15-16
Table 2a.1: Beneficial uses of <i>Carica papaya</i>	29-30
Table 2a. 1: Serum Biochemical Parameters of Acute studies	35
Table 2a.2: Complete Blood count of Rats treated with aqueous extract of <i>Carica papaya</i> leaf extract	37
Table 5.1: Primer Sequences	128
Table 5.2: Respective restriction enzymes used in PCR – RFLP and their properties	129
Table 5.3: Distribution of IL-4 C-590T genotype in ITP patients	130
Table 5.4: Distribution of IL-4-Intron 3 VNTR genotype in ITP patients	131
Table 5.5: Distribution of IL-10-592 genotype in ITP patients	132
Table 5.6: Distribution of IL-10-1082 genotype in ITP patients	133
Table 5.7: Distribution of TNFA G-308A genotype in ITP patients	134
Table 5.8: Distribution of TNF B G+252A genotype in ITP patients	135